Saturday, 31 July 2010

Paracold




Paracold may be available in the countries listed below.


Ingredient matches for Paracold



Paracetamol

Paracetamol is reported as an ingredient of Paracold in the following countries:


  • Vietnam

International Drug Name Search

Ramipril Ivax




Ramipril Ivax may be available in the countries listed below.


Ingredient matches for Ramipril Ivax



Ramipril

Ramipril is reported as an ingredient of Ramipril Ivax in the following countries:


  • Latvia

International Drug Name Search

Wednesday, 28 July 2010

Acamol




Acamol may be available in the countries listed below.


Ingredient matches for Acamol



Paracetamol

Paracetamol is reported as an ingredient of Acamol in the following countries:


  • Chile

  • Israel

International Drug Name Search

Menitazine




Menitazine may be available in the countries listed below.


Ingredient matches for Menitazine



Betahistine

Betahistine dimesilate (a derivative of Betahistine) is reported as an ingredient of Menitazine in the following countries:


  • Japan

International Drug Name Search

Monday, 26 July 2010

Deratin Comprimidos




Deratin Comprimidos may be available in the countries listed below.


Ingredient matches for Deratin Comprimidos



Chlorhexidine

Chlorhexidine dihydrochloride (a derivative of Chlorhexidine) is reported as an ingredient of Deratin Comprimidos in the following countries:


  • Spain

International Drug Name Search

Friday, 23 July 2010

Fluoxetin




Fluoxetin may be available in the countries listed below.


Ingredient matches for Fluoxetin



Fluoxetine

Fluoxetine is reported as an ingredient of Fluoxetin in the following countries:


  • Vietnam

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Fluoxetin in the following countries:


  • Bosnia & Herzegowina

  • Norway

  • Poland

International Drug Name Search

Wednesday, 21 July 2010

Captopril / Hydrochlorothiazide Qualimed




Captopril/Hydrochlorothiazide Qualimed may be available in the countries listed below.


Ingredient matches for Captopril/Hydrochlorothiazide Qualimed



Captopril

Captopril is reported as an ingredient of Captopril/Hydrochlorothiazide Qualimed in the following countries:


  • France

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Captopril/Hydrochlorothiazide Qualimed in the following countries:


  • France

International Drug Name Search

Sunday, 18 July 2010

Metoserpate Hydrochloride




Metoserpate Hydrochloride may be available in the countries listed below.


Ingredient matches for Metoserpate Hydrochloride



Metoserpate

Metoserpate Hydrochloride (BANM, USAN) is also known as Metoserpate (Rec.INN)

International Drug Name Search

Glossary

BANMBritish Approved Name (Modified)
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Saturday, 17 July 2010

Ipacillin




Ipacillin may be available in the countries listed below.


Ingredient matches for Ipacillin



Ampicillin

Ampicillin is reported as an ingredient of Ipacillin in the following countries:


  • Peru

International Drug Name Search

Friday, 16 July 2010

Ivermec




Ivermec may be available in the countries listed below.


Ingredient matches for Ivermec



Ivermectin

Ivermectin is reported as an ingredient of Ivermec in the following countries:


  • Brazil

International Drug Name Search

Thursday, 15 July 2010

Sulfatrim Pediatric


Sulfatrim Pediatric is a brand name of sulfamethoxazole/trimethoprim, approved by the FDA in the following formulation(s):


SULFATRIM PEDIATRIC (sulfamethoxazole; trimethoprim - suspension; oral)



  • Manufacturer: ACTAVIS MID ATLANTIC

    Approval date: January 7, 1983

    Strength(s): 200MG/5ML;40MG/5ML [AB]

Has a generic version of Sulfatrim Pediatric been approved?


Yes. The following products are equivalent to Sulfatrim Pediatric:


SULFAMETHOXAZOLE AND TRIMETHOPRIM (sulfamethoxazole; trimethoprim suspension; oral)



  • Manufacturer: AUROBINDO PHARMA

    Approval date: June 8, 2010

    Strength(s): 200MG/5ML;40MG/5ML [AB]


  • Manufacturer: VINTAGE

    Approval date: January 24, 2007

    Strength(s): 200MG/5ML;40MG/5ML [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sulfatrim Pediatric. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Sulfatrim Pediatric.

See also...

  • Sulfatrim Pediatric Consumer Information (Cerner Multum)
  • Sulfatrim Pediatric Advanced Consumer Information (Micromedex)
  • Sulfamethoxazole/Trimethoprim Consumer Information (Wolters Kluwer)
  • Sulfamethoxazole/Trimethoprim Suspension Consumer Information (Wolters Kluwer)
  • Sulfamethoxazole/Trimethoprim Tablets Consumer Information (Wolters Kluwer)
  • Sulfamethoxazole and trimethoprim Consumer Information (Cerner Multum)
  • Apo-Sulfatrim Advanced Consumer Information (Micromedex)
  • Novo-Trimel Advanced Consumer Information (Micromedex)
  • Nu-Cotrimox Advanced Consumer Information (Micromedex)
  • Septa Pediatric Advanced Consumer Information (Micromedex)
  • Sulfamethoxazole/trimethoprim Advanced Consumer Information (Micromedex)
  • Sulfamethoxazole/trimethoprim Intravenous Advanced Consumer Information (Micromedex)
  • Trimethoprim and sulfamethoxazole Advanced Consumer Information (Micromedex)
  • Trimethoprim and sulfamethoxazole Intravenous Advanced Consumer Information (Micromedex)

Tuesday, 13 July 2010

Cefurox Basics




Cefurox Basics may be available in the countries listed below.


Ingredient matches for Cefurox Basics



Cefuroxime

Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Cefurox Basics in the following countries:


  • Germany

International Drug Name Search

Monday, 12 July 2010

Cipralan




Cipralan may be available in the countries listed below.


Ingredient matches for Cipralan



Cibenzoline

Cibenzoline is reported as an ingredient of Cipralan in the following countries:


  • Luxembourg

Cibenzoline succinate (a derivative of Cibenzoline) is reported as an ingredient of Cipralan in the following countries:


  • Belgium

  • France

International Drug Name Search

Sunday, 11 July 2010

BexxarTherapeutic


Generic Name: tositumomab (TOE si too MOE mab)

Brand Names: Bexxar Dosimetric, BexxarTherapeutic


What is BexxarTherapeutic (tositumomab)?

Tositumomab is a monoclonal antibody that is linked with radioactive iodine I-131. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage.


Tositumomab is used to treat certain forms of non-Hodgkin's lymphoma. It is usually given after other medications have been tried without successful treatment.


Tositumomab may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about BexxarTherapeutic (tositumomab)?


You should not receive this medication if you are allergic to mouse proteins, or if you have ever had an allergic reaction to a monoclonal antibody.

Before you receive tositumomab, tell your doctor if you have kidney disease or severe bone marrow suppression.


Tositumomab can cause damage to the thyroid gland of an unborn baby if the mother receives this medication during pregnancy. You should not receive this medication if you are pregnant.

Tositumomab can be harmful to an unborn baby whether the father or the mother receives this medication at the time of conception. Use effective birth control to prevent pregnancy during your treatment, whether you are a man or a woman. Continue using birth control for at least 12 months after you have received tositumomab.


Do not receive a "live" vaccine just after you receive tositumomab. After you are treated with tositumomab, your body will retain radioactive material for several days. During this time you will be giving off a small amount of radiation to others around you. Your caregivers should give you instructions about how to avoid exposing other people to radiation until this effect wears off. Follow these instructions carefully. Take all medications your doctor prescribes to help protect your thyroid gland when you receive tositumomab. You may need to have blood tests to check your thyroid function at regular intervals for the rest of your life. Visit your doctor regularly.

What should I discuss with my health care provider before I receive BexxarTherapeutic (tositumomab)?


You should not receive this medication if you are allergic to mouse proteins, or if you have ever had an allergic reaction to a monoclonal antibody. FDA pregnancy category X. Tositumomab can cause damage to the thyroid gland of an unborn baby if the mother receives this medication during pregnancy. You should not receive this medication if you are pregnant.

Tositumomab can be harmful to an unborn baby whether the father or the mother receives this medication at the time of conception. Use effective birth control to prevent pregnancy during your treatment, whether you are a man or a woman. Continue using birth control for at least 12 months after you have received tositumomab.


Some people treated with tositumomab later developed leukemia or other cancers. However, it has not been determined whether this medication actually increases the risk of causing other cancers. Talk with your doctor about your individual risk.


How is tositumomab given?


Before and during your tositumomab treatment, you will be given other medications to protect your thyroid gland and to help prevent allergic reactions. You may need to keep taking some of these medications for up to 2 weeks after your treatment.

The tositumomab treatment is usually given in two steps over a span of 7 days. In the first treatment step, you will receive the two injections just before you undergo an x-ray scan of your entire body. This scan will show your doctor how well the radioactive ingredients of the tositumomab injections are circulating throughout your body. You may receive at least 2 more scans over the next 6 or 7 days.


Based on the results of your scans, your doctor will determine whether or not to give the second step of tositumomab treatment, and how large your dose should be.


In step 2 of the treatment, you will again receive the two injections one at a time. These injections are considered your therapeutic dose. The 2-step tositumomab treatment is usually given only once, so you are not likely to receive a second course of treatment with this medication.


Wash your hands often to prevent infections. After you are treated with tositumomab, your body will retain radioactive material for several days. During this time you will be giving off a small amount of radiation to others around you. Your caregivers should give you instructions about how to avoid exposing other people to radiation until this effect wears off.

Tositumomab can increase your risk of developing hypothyroidism (underactive thyroid). Hypothyroidism can be treated with daily thyroid replacement medication.


Take all medications your doctor prescribes to help protect your thyroid gland when you receive tositumomab. You may need to have blood tests to check your thyroid function at regular intervals for the rest of your life. Visit your doctor regularly.

Tositumomab can cause you to have unusual results with certain medical tests. You may also have an allergic reaction to diagnostic tests or treatments using mouse proteins or monoclonal antibodies. Tell any doctor who treats you that you have been treated with tositumomab.


What happens if I miss a dose?


Since tositumomab is given in a controlled setting by a healthcare professional, it is not likely that you will miss a dose.


What happens if I overdose?


An overdose of this medication is very unlikely to occur.


What should I avoid after receiving BexxarTherapeutic (tositumomab)?


Do not receive a "live" vaccine just after you receive tositumomab. Ask your doctor how long after your treatment you should wait before receiving any vaccines.

Avoid sports or activities that may increase your risk of bleeding or injury. Use a soft toothbrush to keep your gums from bleeding. Take extra care not to cut yourself while shaving.


Avoid handling any of your body fluids without wearing latex rubber gloves. If another person is handling your fluids (vomit, stools, or urine), they should wear gloves, eye protection, and a mask to cover the nose and mouth.

When cleaning any spills of bodily fluid, use only disposable cleaning cloths that can be flushed down a toilet. Ask your doctor or health department how to dispose of any bodily fluid spills that cannot be flushed down a toilet.


To protect others from exposure to the radioactive matter in your body, try to stay at least 6 feet away from other people, especially children or pregnant women. Follow these steps for several days after your tositumomab treatment ends:



  • Avoid crowds and public places.




  • Avoid traveling on long trips.




  • Do not share a bed or bathroom with another person.




  • Sit on the toilet while urinating and flush 3 times with the lid down after use.




  • Always wash your hands after using the bathroom.




  • Do not share a towel, wash cloth, or toothbrush with another person.




  • Do not share drinking glasses, plates, or silverware.




  • Wait at least 1 week before washing any of the clothing and bed or bath linens you have used during the week after your treatment. Keep these items separate from the laundry of other people in your home.




  • Wash your clothing and other items separately from other laundry in your home.



BexxarTherapeutic (tositumomab) side effects


Some people receiving tositumomab have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregivers right away if you feel dizzy, nauseated, light-headed, sweaty, or short of breath, or if you have fever or chills during the injection. Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:



  • pale skin, easy bruising or bleeding, unusual weakness;




  • black, bloody, or tarry stools;




  • blood in your urine;




  • fever, chills, sore throat, body aches, flu symptoms;




  • cough with yellow or green mucus; or




  • stabbing chest pain, feeling short of breath.



Less serious side effects may include:



  • decreased energy;




  • weight gain;




  • headache;




  • joint or muscle pain;




  • feeling weak or irritable;




  • increased thirst and hot, dry skin;




  • nausea, vomiting, diarrhea, stomach pain;




  • loss of appetite;




  • mild itching or skin rash;




  • runny or stuffy nose; or




  • pain, itching, swelling, or redness around your IV needle.



What other drugs will affect BexxarTherapeutic (tositumomab)?



More BexxarTherapeutic resources


  • BexxarTherapeutic Use in Pregnancy & Breastfeeding
  • BexxarTherapeutic Drug Interactions
  • BexxarTherapeutic Support Group
  • 0 Reviews for BexxarTherapeutic - Add your own review/rating


  • Tositumomab Monograph (AHFS DI)

  • tositumomab Intravenous Advanced Consumer (Micromedex) - Includes Dosage Information

  • Tositumomab MedFacts Consumer Leaflet (Wolters Kluwer)



Compare BexxarTherapeutic with other medications


  • Diagnosis and Investigation


Where can I get more information?


  • Your doctor or pharmacist can provide more information about tositumomab.


Friday, 9 July 2010

Amlodipin AL




Amlodipin AL may be available in the countries listed below.


Ingredient matches for Amlodipin AL



Amlodipine

Amlodipine mesilate (a derivative of Amlodipine) is reported as an ingredient of Amlodipin AL in the following countries:


  • Germany

  • Romania

International Drug Name Search

Thursday, 8 July 2010

Lovask




Lovask may be available in the countries listed below.


Ingredient matches for Lovask



Amlodipine

Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Lovask in the following countries:


  • Indonesia

International Drug Name Search

Wednesday, 7 July 2010

Permapen




Ingredient matches for Permapen



Benzylpenicillin

Benzylpenicillin benzathine (a derivative of Benzylpenicillin) is reported as an ingredient of Permapen in the following countries:


  • United States

International Drug Name Search

Drixoral Non-Drowsy Sustained-Release Capsules


Pronunciation: soo-doe-e-FED-rin
Generic Name: Pseudoephedrine
Brand Name: Sudafed 12 Hour


Drixoral Non-Drowsy Sustained-Release Capsules are used for:

Relieving congestion due to colds, flu, hay fever, and other allergies. It may also be used for other conditions as determined by your doctor.


Drixoral Non-Drowsy Sustained-Release Capsules are a decongestant. It works by reducing swelling and constricting blood vessels in the nasal passages, allowing you to breathe more easily.


Do NOT use Drixoral Non-Drowsy Sustained-Release Capsules if:


  • you are allergic to any ingredient in Drixoral Non-Drowsy Sustained-Release Capsules

  • you are taking furazolidone or have taken a monoamine oxidase (MAO) inhibitor (eg, phenelzine) in the last 14 days

  • you have severe high blood pressure, severe heart blood vessel disease, a rapid heartbeat, or severe heart problems

Contact your doctor or health care provider right away if any of these apply to you.



Before using Drixoral Non-Drowsy Sustained-Release Capsules:


Some medical conditions may interact with Drixoral Non-Drowsy Sustained-Release Capsules. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a history of heart problems, diabetes, glaucoma, an enlarged prostate or other prostate problems, adrenal gland problems, high blood pressure, seizures, stroke, blood vessel problems, or an overactive thyroid

Some MEDICINES MAY INTERACT with Drixoral Non-Drowsy Sustained-Release Capsules. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Rauwolfia derivatives (eg, reserpine) because the effectiveness of Drixoral Non-Drowsy Sustained-Release Capsules may be decreased

  • Beta-blockers (eg, propranolol), cocaine, furazolidone, indomethacin, methyldopa, MAO inhibitors (eg, phenelzine), oxytocic medicines (eg, oxytocin), rauwolfia derivatives (eg, reserpine), or tricyclic antidepressants (eg, amitriptyline) because the actions and side effects of Drixoral Non-Drowsy Sustained-Release Capsules may be increased

  • Bromocriptine, catechol-O-methyltransferase (COMT) inhibitors (eg, entacapone), digoxin, or droxidopa because the actions and side effects of these medicines may be increased

  • Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because its effectiveness may be decreased by Drixoral Non-Drowsy Sustained-Release Capsules

This may not be a complete list of all interactions that may occur. Ask your health care provider if Drixoral Non-Drowsy Sustained-Release Capsules may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Drixoral Non-Drowsy Sustained-Release Capsules:


Use Drixoral Non-Drowsy Sustained-Release Capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Drixoral Non-Drowsy Sustained-Release Capsules with food, water, or milk to minimize stomach irritation.

  • Swallow Drixoral Non-Drowsy Sustained-Release Capsules whole. Do not break, crush, or chew before swallowing.

  • If you miss a dose of Drixoral Non-Drowsy Sustained-Release Capsules and are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Drixoral Non-Drowsy Sustained-Release Capsules.



Important safety information:


  • Drixoral Non-Drowsy Sustained-Release Capsules may cause dizziness. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Drixoral Non-Drowsy Sustained-Release Capsules. Using Drixoral Non-Drowsy Sustained-Release Capsules alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks.

  • If your symptoms do not improve within 7 days or if you develop a high fever, check with your doctor.

  • If you have trouble sleeping, ask your pharmacist or doctor about the best time to take Drixoral Non-Drowsy Sustained-Release Capsules.

  • Do not take diet or appetite control medicines while you are taking Drixoral Non-Drowsy Sustained-Release Capsules.

  • Drixoral Non-Drowsy Sustained-Release Capsules contains pseudoephedrine. Before you begin taking any new prescription or nonprescription medicine, read the ingredients to see if it also contains pseudoephedrine. If it does or if you are uncertain, contact your doctor or pharmacist.

  • Diabetes patients - Drixoral Non-Drowsy Sustained-Release Capsules may affect your blood sugar. Check blood sugar levels closely and ask your doctor before adjusting the dose of your diabetes medicine.

  • Use Drixoral Non-Drowsy Sustained-Release Capsules with caution in the ELDERLY because they may be more sensitive to its effects.

  • Use Drixoral Non-Drowsy Sustained-Release Capsules with extreme caution in CHILDREN younger than 12 years of age. Safety and effectiveness in this age group have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, discuss with your doctor the benefits and risks of using Drixoral Non-Drowsy Sustained-Release Capsules during pregnancy. It is unknown if Drixoral Non-Drowsy Sustained-Release Capsules are excreted in breast milk. If you are or will be breast-feeding while you are using Drixoral Non-Drowsy Sustained-Release Capsules, check with your doctor or pharmacist to discuss the risks to your baby.


Possible side effects of Drixoral Non-Drowsy Sustained-Release Capsules:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Difficulty urinating; dizziness; headache; nausea; nervousness; restlessness; sleeplessness; stomach irritation.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Drixoral Non-Drowsy side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include confusion; hallucinations; irregular or unusually slow or rapid heartbeat; rapid breathing; seizures.


Proper storage of Drixoral Non-Drowsy Sustained-Release Capsules:

Store Drixoral Non-Drowsy Sustained-Release Capsules at room temperature, between 59 and 77 degrees F (15 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Drixoral Non-Drowsy Sustained-Release Capsules out of the reach of children and away from pets.


General information:


  • If you have any questions about Drixoral Non-Drowsy Sustained-Release Capsules, please talk with your doctor, pharmacist, or other health care provider.

  • Drixoral Non-Drowsy Sustained-Release Capsules are to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Drixoral Non-Drowsy Sustained-Release Capsules. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Drixoral Non-Drowsy resources


  • Drixoral Non-Drowsy Side Effects (in more detail)
  • Drixoral Non-Drowsy Use in Pregnancy & Breastfeeding
  • Drixoral Non-Drowsy Drug Interactions
  • Drixoral Non-Drowsy Support Group
  • 1 Review for Drixoral Non-Drowsy - Add your own review/rating


Compare Drixoral Non-Drowsy with other medications


  • Nasal Congestion

Tuesday, 6 July 2010

Fluoxetina Cinfa




Fluoxetina Cinfa may be available in the countries listed below.


Ingredient matches for Fluoxetina Cinfa



Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Fluoxetina Cinfa in the following countries:


  • Portugal

  • Spain

International Drug Name Search

Sunday, 4 July 2010

Ezetim




Ezetim may be available in the countries listed below.


Ingredient matches for Ezetim



Ezetimibe

Ezetimibe is reported as an ingredient of Ezetim in the following countries:


  • Bangladesh

International Drug Name Search

Saturday, 3 July 2010

Medinol




Medinol may be available in the countries listed below.


UK matches:

  • Medinol Paediatric Paracetamol Oral Suspension BP 120mg/5ml (SPC)

Ingredient matches for Medinol



Paracetamol

Paracetamol is reported as an ingredient of Medinol in the following countries:


  • Malta

  • United Kingdom

International Drug Name Search

Glossary

SPC Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Thursday, 1 July 2010

Rifampicina Iqfarma




Rifampicina Iqfarma may be available in the countries listed below.


Ingredient matches for Rifampicina Iqfarma



Rifampicin

Rifampicin is reported as an ingredient of Rifampicina Iqfarma in the following countries:


  • Peru

International Drug Name Search